Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BrainAurora Medical Partners with Tokyo Lifestyle to Launch AI-Powered Digital Health Platform for Elderly Cognitive Care Across Asia

Fineline Cube Mar 30, 2026
Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial

Fineline Cube Mar 30, 2026
Company Drug

Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target

Fineline Cube Mar 30, 2026
Company Drug

UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis

Fineline Cube Oct 14, 2025

UCB S.A. (EBR: UCB), a global biopharmaceutical company, announced today that the National Medical Products...

Company Drug

Mabwell Bioscience Receives NMPA IND Approval for 7MW4911 CDH17‑Targeting ADC in Advanced Solid Tumors

Fineline Cube Oct 14, 2025

Mabwell Bioscience (SHA: 688062) announced today that the National Medical Products Administration (NMPA) has granted...

Company Drug

GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults

Fineline Cube Oct 14, 2025

GlaxoSmithKline (NYSE: GSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval...

Company Drug

Arcutis Biotherapeutics Receives FDA Approval for ZORYVE (Roflumilast) Cream in Children 2‑5 Years with Atopic Dermatitis

Fineline Cube Oct 14, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), the U.S. partner of Huadong Medicine Co., Ltd. (SHE: 000963), announced today that...

Company Drug

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

Fineline Cube Oct 14, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...

Company Drug

ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease

Fineline Cube Oct 14, 2025

ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Drug

Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14

Fineline Cube Oct 14, 2025

Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...

Company Deals Drug

Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China

Fineline Cube Oct 14, 2025

Boehringer Ingelheim (BI) announced today the official start‑up of its local manufacturing plan for the diabetes...

Company Drug

Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B

Fineline Cube Oct 13, 2025

Amoytop Biotech Co. Ltd. (SHA: 688278) announced today that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China

Fineline Cube Oct 13, 2025

Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that it has completed an equity...

Company Drug

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer

Fineline Cube Oct 13, 2025

Jiangsu Chia Tai  Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of China‑listed Sino Biopharmaceutical Ltd....

Company Drug

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Fineline Cube Oct 13, 2025

Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...

Company Drug

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Fineline Cube Oct 13, 2025

China‑listed Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the National Medical Products...

Company Drug

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621

Fineline Cube Oct 13, 2025

China‑based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category 1 innovative drug BH1621 has...

Company Deals

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

Fineline Cube Oct 13, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune, Inc....

Drug

Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 13, 2025

Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...

Drug

China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor

Fineline Cube Oct 13, 2025

The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received...

Drug Medical Device Policy / Regulatory

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China

Fineline Cube Oct 13, 2025

The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...

Company Deals Drug

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

Fineline Cube Oct 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...

Company Medical Device

Peijia Medical Secures NMPA Approval for GeminiOne TEER System

Fineline Cube Oct 11, 2025

Peijia Medical Limited (HKG: 9996) announced today that the National Medical Products Administration (NMPA) of...

Posts pagination

1 … 71 72 73 … 642

Recent updates

  • RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
  • Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial
  • Hansoh Pharma Reports 22.6% Revenue Growth in 2025, Driven by Oncology and $4.54B in Global Licensing Deals
  • Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M
  • Eli Lilly’s Lebrikizumab Demonstrates Four-Year Sustained Efficacy in Atopic Dermatitis, Reinforcing IL-13 as Core Therapeutic Target
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin

Company Drug

Eli Lilly’s Taltz-Zepbound Combo Shows Superior Efficacy in Obese Psoriatic Arthritis Patients in Phase IIIb TOGETHER-PsA Trial

Company

Hansoh Pharma Reports 22.6% Revenue Growth in 2025, Driven by Oncology and $4.54B in Global Licensing Deals

Company

Insilico Medicine Reports $56.2M Revenue in 2025 Amid Strategic Pipeline Buildout; Cash Reserves Stand at $393M

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.